Nephrology

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Strong results motivate the ADA to update its Standard of Care for patients with diabetes.

Can a patient with type 2 diabetes diagnosed with dementia have increased rate of mortality?

Featuring exclusive comments from Dr. George Bakris
Studies are rarely stopped early; when it happens, we should take notice of the results.

Metformin may help lower the risk of cardiovascular events and death in patients with moderate to severe renal function.

Dapagliflozin’s updated package insert confirms efficacy and safety profile for patients with moderate chronic kidney disease.

Older adults with diabetes and chronic kidney disease (CKD) are at an increased risk of cognitive impairment and dementia, frailty, dysglycemia, and polypharmacy.

In patients with stage 3 kidney disease, metformin use may be safe and may reduce the risk of mortality and cardiovascular events.

Use of albuminuria level changes as the endpoint to determine need to reduce albumin-to-creatinine ratio.

Change in albuminuria as surrogate endpoint for progression of chronic kidney disease strongly supported by biological plausibility, but empirical evidence to support its validity in epidemiological studies lacking.